Treatment of Candida infection: A view from the trenches!

Current Opinion in Infectious Diseases

Volumn 18, Issue 6, 2005, Pages 490-495

  Bustamante, Carlos I ^a,b,c  

^a Memorial Health Care System   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Edelstein and Bustamante MDs PA   (United States)

Author keywords

Antifungals; Candidemia

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE; VORICONAZOLE;

CANDIDA ALBICANS; CANDIDIASIS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SENSITIVITY; EMPIRICISM; EVIDENCE BASED MEDICINE; HEALTH CARE SYSTEM; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTENSIVE CARE UNIT; RECURRENT INFECTION; REVIEW; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

EID: 27744432658     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000191516.43792.61     Document Type: Review

References (21)

1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892.
2. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic 4iseases in the United States, 1980-1997. Clin Infect Dis 2001; 33:641-647.
3. Pfaller MA, Diekema DJ, Jones RN, et al. SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol; 2000; 40:852-856.
4. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE Participant Group. Diagn Microbiol Infect Dis 1998; 30:121-129.
5. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40:1298-1302.
6. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001; 7 (Suppl 2):1-7.
7. Baran J Jr, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infec Dis 2001; 33:137-139.
8. Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189. Consensus paper of the official guidelines for the treatment of Candida infections.
9. Pfaller MA, Jones RN, Doerm GV, et al. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrobial Agents and Chemother 2000; 44:747-751.
10. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39:3254-3259.
11. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41 (Suppl 6):S389-S393. This paper summarizes risk factors and mortality in the critical care setting.
12. Macphail GLP, Taylor GD, Buchanan-Chell M, et al. Epidemiology and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002; 45:141-145. Experience in community hospitals in Canada.
13. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of Candida glabrata to seven systemically active antifungal agents: a global assessment form the ARTEMIS Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42:3142-3146. This paper illustrates the geographical emergence and prevalence of C. glabrata.
14. Cheng M-F, Yu K-W, Tang R-B, et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagnost Microbiol Infect Dis 2004; 48:33-37. This paper describes experience with Candida bloodstream infections in Taiwan.
15. Trick W, Fridkin S, Edwards J, Hospitals NNISI. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630.
16. Gaynes RP, Horan TC. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital epidemiology and infection control. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. pp. 1285-1317.
17. Pasqualotto AC, Nedel WL, Machado TS, Severo LC. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial candidaemia. J Hosp Infect 2005; 60:129-134. Risk factors and mortality of Candida blood stream infections in Brasil.
18. Verma AK, Prasad KN, Singh M, et al. Candidaemia in patients of a tertiary health care hospital from north India. Indian J Med Res 2003; 117:122-128. Candidemia in a tertiary hospital in North India.
19. Valles J. Bacteremias in intensive care. Enferm Infec Microbiol Clin 1997; 15 (Suppl 3):8-13.
20. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34:281-286.
21. Kullberg BJ, Pappas P, Ruhnke M, et al. Voriconazole compared to a strategy of amphotericin B followed by fluconazole for treatment of candidaemia in non-neutropenic patients. In: 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic; 1-4 May 2004.